Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?
Regeneron Pharmaceuticals (NASDAQ: REGN) shares have made little headway since the disappointing launch of Praluent in 2015. Perhaps, the company's latest drug, cemiplimab, can change that. Regeneron and Sanofi (NYSE: SNY) reported updated data for cemiplimab in skin cancer earlier today and based on that data, the two companies have begun a rolling application for FDA approval. Will this drug move the needle for these companies?
Cemiplimab belongs to a class of drugs called PD-1 inhibitors that help disable a cancer's ability to escape detection by the immune system.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Regeneron Pharmaceuticals Inc. Stock
€922.40
0.240%
With 53 Buy predictions and 1 Sell predictions Regeneron Pharmaceuticals Inc. is one of the favorites of our community.
As a result the target price of 1080 € shows a slightly positive potential of 17.09% compared to the current price of 922.4 € for Regeneron Pharmaceuticals Inc..
